US Food and Drug Administration (2020) FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer. US Food and Drug Administration, Silver Spring.
has been cited by the following article:
Related Articles: